Forty Seven Inc.
FTSV:NASDAQ
Forty Seven is a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. Forty Seven focus its efforts on targeting the CD47 pathway as a way to engage macrophages in fighting tumors.
Streetwise Company Fact Sheet
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
